Supplementary material: Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis

This is a peer-reviewed supplementary table for the article 'Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1. Treatment switch details.Summary: Aim: Real-world treatment data for psoriatic arthritis are limited. We evaluated switch rates, adherence, and costs for patients initiating apremilast versus tumor necrosis factor inhibitor (TNFi) and interleukin inhibitor (ILi) among biologic-naive psoriatic arthritis patients. Materials & methods: This retrospective analysis used IBM MarketScan claims data to assess treatment switches, adherence and costs. Results: Twelve-month switch rates were significantly lower for apremilast versus TNFi (15.5% vs 26.6%; p < 0.0001) and similar to ILi (15.5% vs 14.0%; p = 0.71). Apremilast initiators had lower total costs versus TNFi and ILi (US$39,854 vs US$57,243 and US$65,687; p < 0.05) and adherence was slightly lower versus TNFi and higher versus ILi. Conclusion: Biologic-naive apremilast initiators had lower switch rates versus TNFi initiators and lower total costs versus TNFi or ILi initiators.

本表为发表于《比较疗效研究杂志》的论文《与生物制剂相比，在初治银屑病关节炎患者中，阿普米单抗与肿瘤坏死因子抑制剂（TNFi）和白细胞介素抑制剂（ILi）的切换率及总成本》的同行评审补充表格。补充表1. 治疗切换详情摘要：目的：银屑病关节炎的真实世界治疗数据有限。本研究旨在评估对生物制剂初治的银屑病关节炎患者启动阿普米单抗与启动TNFi和ILi患者的切换率、依从性和成本。材料与方法：本研究采用IBM MarketScan索赔数据进行的回顾性分析，以评估治疗切换、依从性和成本。结果：与TNFi相比，阿普米单抗的12个月切换率显著较低（15.5% vs 26.6%，p < 0.0001），与ILi相似（15.5% vs 14.0%，p = 0.71）。与TNFi和ILi相比，阿普米单抗的启动者具有更低的总体成本（美国美元39,854 vs 57,243和65,687；p < 0.05），依从性略低于TNFi，而高于ILi。结论：与TNFi启动者相比，生物制剂初治的阿普米单抗启动者具有更低的切换率，与TNFi或ILi启动者相比，具有更低的总体成本。